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Dihydrotanshinone-I interferes 
with the RNA-binding activity 
of HuR affecting its post-
transcriptional function
Vito Giuseppe D’Agostino1, Preet Lal1, Barbara Mantelli1, Christopher Tiedje2, 
Chiara Zucal1, Natthakan Thongon1, Matthias Gaestel2, Elisa Latorre1, Luciana Marinelli3, 
Pierfausto Seneci4, Marialaura Amadio5 & Alessandro Provenzani1
Post-transcriptional regulation is an essential determinant of gene expression programs in 
physiological and pathological conditions. HuR is a RNA-binding protein that orchestrates 
the stabilization and translation of mRNAs, critical in inflammation and tumor progression, 
including tumor necrosis factor-alpha (TNF). We identified the low molecular weight compound 
15,16-dihydrotanshinone-I (DHTS), well known in traditional Chinese medicine practice, through 
a validated high throughput screening on a set of anti-inflammatory agents for its ability to 
prevent HuR:RNA complex formation. We found that DHTS interferes with the association step 
between HuR and the RNA with an equilibrium dissociation constant in the nanomolar range in 
vitro (Ki = 3.74 ± 1.63 nM). In breast cancer cell lines, short term exposure to DHTS influences 
mRNA stability and translational efficiency of TNF in a HuR-dependent manner and also other 
functional readouts of its post-transcriptional control, such as the stability of selected pre-mRNAs. 
Importantly, we show that migration and sensitivity of breast cancer cells to DHTS are modulated 
by HuR expression, indicating that HuR is among the preferential intracellular targets of DHTS. 
Here, we disclose a previously unrecognized molecular mechanism exerted by DHTS, opening new 
perspectives to therapeutically target the HuR mediated, post-transcriptional control in inflammation 
and cancer cells.
Post-transcriptional control of messenger RNA, coordinated by RNA-binding proteins (RBPs) and small 
or long non-coding RNAs, is an essential determinant of protein expression. Altered mRNA stability of 
pro-inflammatory cytokines tightly correlates with several pathological conditions such as inflammation, 
autoimmune disorders and cancer1. A prominent example of cytokine subjected to post-transcriptional 
control is tumor necrosis factor alpha (TNF-alpha or TNF), one of the main mediators of chronic 
inflammation associated with malignant cell transformation, growth and tumor progression2. Depletion 
of several RBPs can alter TNF protein production, leading to exacerbated chronic inflammatory dis-
ease both in mice and in humans3, supporting the relevance of in vivo post-transcriptional control on 
TNF mRNA. The half-life of this transcript is influenced by competitive binding of RBPs to adenylate- 
and uridinylate-rich elements (AU-rich elements or AREs) and by a constitutive decay element (CDE) 
in its 3′ -untranslated region (UTR)4,5. Notably, it has been shown that the stability and translational 
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efficiency of TNF mRNA is dependent on the p38 MAPK pathway, whose activation modulates the 
cytoplasmic equilibrium of tristetraprolin (TTP or Zfp36) and HuR/ELAVL1 proteins6. Whilst TTP is an 
anti-inflammatory RBP favoring rapid mRNA degradation, HuR stabilizes transcripts and promotes their 
poly-ribosomes engagement for active translation. This post-transcriptional function of HuR has been 
described for a wide number of transcripts bearing AU-rich elements, whose turnover is critical for cell 
proliferation, tumor cell survival, angiogenesis and metastasis7–10. Sporadically, anti-inflammatory agents 
have been reported to post-transcriptionally modulate cytokines, including TNF, with a variable involve-
ment of the p38 MAPK pathway, as in the case of KL-103711, s-curvularin12, LCY-2-CHO13. However, the 
direct and specific modulation of defined trans-acting factors has remained elusive. On the other side, 
systematic investigations, based on the direct evaluation of a post-transcriptional read-out have shown 
the feasibility of considering RBPs as potential drug targets14–16. Interestingly, resveratrol was found to 
suppress activation-induced gene expression in T-cell via a post-transcriptional mechanism and its effects 
were rescued by the RBP HuR. The same molecule was found to exert its post-transcriptional effects 
by regulating the RBP KSRP, suggesting that resveratrol changes the mRNA stability of HuR-targeted 
transcripts by enhancing the 3′ -UTR binding of KSRP and replacing HuR from the same 3′ -UTR 
sequences16. Here we demonstrate that 15,16-dihydrotanshinone-I (DHTS), identified through a bio-
chemical high-throughput screening among a set of anti-inflammatory agents, inhibits the HuR-RNA 
complex formation in vitro in low nanomolar range. DHTS belongs to the bioactive family of diterpenic 
tanshinones, extracted from the roots of Salvia miltiorrhiza and well-known in traditional Chinese med-
icine practice. Tanshinones are anti-inflammatory agents used for treatment of cardiovascular diseases17 
and during the last years they have been proposed as anti-cancer agents due their anti-proliferative, 
anti-angiogenic and pro-apoptotic activities against a broad spectrum of tumors18,19. We provide evi-
dences that interference of DHTS on HuR activity determines a post-transcriptional influence of TNF 
mRNA processing, showing a previously unrecognized molecular mechanism for this class of small mol-
ecules. In addition, we show that cytotoxicity and migration properties of breast cancer cell lines treated 
with DHTS are influenced by HuR dosage, supporting the post-transcriptional effect of this compound 
as a new, therapeutically relevant molecular mechanism.
Results
15,16-Dihydrotanshinone I (DHTS) interferes with HuR-RNA interaction in vitro. The mRNA 
stabilizing effects of HuR have been frequently investigated by studying the post-transcriptional control 
of key pro-inflammatory genes like COX-2, TNF or specific cytokines such as IL1720–22. We hypothe-
sized that anti-inflammatory small molecules could integrate a post-transcriptional layer of influence on 
mRNAs, in their mechanism of action, by interfering with HuR function. By using a previously validated 
biochemical approach23 involving the 3′ UTR ARE of TNF as RNA probe and a recombinant human HuR 
protein, we screened a set of commercially available anti-inflammatory compounds (a total of 107 listed 
in Supplementary Table S1) for their ability to prevent the rHuR-RNA complex formation. Eight posi-
tive hits were obtained (DHTS, hydrocortisone acetate, amiprilose, flurbiprofen, deracoxib, fluocinolone, 
triamcinolone, dexamethasone). The most potent hit, DHTS (CHEMBL227075 ID in ChEMBL database, 
Z-Score = − 2.69, Fig.  1A and Supplementary Table S1), among the other compounds, confirmed this 
inhibitory activity in RNA electrophoresis mobility shift assays. DHTS did not alter the electrophoretic 
mobility or the stability of the RNA probe even when a 200 fold molar excess (100 μ M) was used in the 
assay (Fig. 1B and Supplementary Fig. S1A), behaving as a validated hit. Saturation binding competitive 
experiments at equilibrium, either by REMSA (Fig.  1C) or AlphaScreen assays (Fig.  1D), indicated an 
equilibrium dissociation constant for DHTS (Ki) of 3.74 ± 1.63 nM, using a Kd equal to 2.5 nM23, and 
IC50 equaling 149 ± 34 nM and 68 ± 16 nM for REMSA or AlphaScreen assays, respectively and accord-
ing to the different concentration of the reagents used. The range of Ki values was also confirmed by 
competitive binding kinetics experiments (Fig.  1E), that revealed an association rate constant (k3) of 
5.38 ± 1.64*106 M−1 min−1 and a dissociation rate constant (k4) of 0.016 ± 0.01 min–1 for DHTS (k4/
k3 = 2.97 ± 0.7 nM). From these data, representing the law of mass action parameters of DHTS, it can 
be inferred that DHTS has a much higher probability to associate with one or both the free ligands, 
rather than to displace a pre-formed protein-RNA complex. Consistently, binding kinetic experiments 
performed either upon pre-incubation of rHuR with different concentrations of DHTS (Fig.  1F), or 
upon pre-incubation of protein and RNA (Fig. 1G), provided evidence that DHTS mainly prevents the 
association between the two ligands. Since the recognition of RNA substrate is determined by the RNA 
recognition domains (RRMs) of HuR, we purified two recombinant HuR isoforms (Supplementary Fig. 
S1B) retaining two different arrangements of RRMs, as depicted in Fig. 2A. As RRM1 and RRM2 are the 
rate-limiting domains for HuR binding activity24, the M1_M2 construct was expected to best recapitulate 
the ability of full-length HuR to bind to RNA, and to be the best target for DHTS. Accordingly, at equilib-
rium, M1_M2 isoform showed a Kd value (2.66 nM) similar to full-lenght HuR. DHTS similarly inhibited 
the M1_M2-RNA complex formation (Ki = 4.12 ± 0.81 nM). Notably, the M2_M3 construct expressed a 
labile protein characterized by higher Kd value (~24 nM) and only limited effects of DHTS were observed. 
In addition, we purified each single RRM domain (M1, M2, M3) from E. coli cells (Supplementary Fig. 
S1C) and analyzed their binding to the RNA probe in the presence of DHTS. The binding of M2 and M3 
was not affected even using 10 μ M of DHTS, while M1 was only marginally affected, being 74% of the 
protein still binding RNA with 5 μ M of DHTS (Supplementary Fig. S1C). Taken together, these results 
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suggest that the compound interferes with RNA binding by affecting a different site from the domain of 
RNA recognition. A putative explanation could reside in the interference by DHTS with the allosteric 
conformational changes of the first two RRMs, disturbing the additional contacts formed with the 
inter-domain linker region during RNA binding24. The in vitro activity of three commercially available 
members of the tanshinone family of compounds was evaluated in our biochemical model. Each tested 
tanshinone showed inhibitory activity (Supplementary Fig. S1D). However, while cryptotanshinone and 
tanshinone IIA were less potent (micromolar range), the potency of tanshinone I was comparable to 
DHTS at equilibrium (Fig. 2B). This indicates how this kind of interference requires either an aromatic 
furan ring (as in tanshinone I), or a reduced dihydrofuran (as in DHTS) on the right portion of the mol-
ecule. Conversely, the left side of tanshinones must contain a planar, aromatic methyl-substituted ring 
(as in DHTS and tanshinone I), rather than a non-planar, dimethyl-substituted cyclohexene ring (as in 
cryptotanshinone and tanshinone IIA). As tanshinone I is poorly soluble in buffers of biochemical assays 
(producing visible precipitates at the highest doses), we used DHTS as reference compound/inhibitor to 
exploit this bioactivity for further experiments.
Albeit the selective profile of DHTS and tanshinones has to be systematically characterized, we 
selected four other RBPs, i.e. Lin28b, TTP, TDP-43 and ELAVL4/HuD, with different structural simi-
larity compared with HuR and tested DHTS as a modulator of their specific protein-RNA interactions 
(Fig.  2C). As expected considering the 78% structural similarity with HuR, only HuD-RNA complex 
formation was affected by DHTS at the reference doses. Conversely, the binding of Lin28b, TTP, and 
TDP-43 to RNA did not appear substantially affected. Taken together, these biochemical data allowed to 
quantitatively determine the DHTS-mediated inhibition of the HuR-RNA complex formation in vitro, 
the highest potency of DHTS among the tested analogs and its selective profile towards other RBPs. 
Then, we decided to deeply investigate the post-transcriptional role of DHTS in a panel of breast cancer 
cell lines, characterized by HuR over-expression25.
DHTS down-regulates TNF mRNA and protein levels. Viability assays measuring intracellular 
ATP levels in different breast cancer cell lines (MCF-7, MDA-MB-231 and SKBR3), showed that about 
50% of cells were not viable after 24 h treatment with 1 μ M DHTS (MCF-7, IC50 = 0.84 μ M, Fig.  3A; 
MDA-MB-231, IC50 = 0.92 μ M, and SKBR3, IC50 = 1.2 μ M, graphs not shown). In MCF-7 cells, caspase 
activation was clearly visible after 24 h of treatment using as low as 0.5 μ M of DHTS. Conversely, at an 
Figure 1. DHTS is an inhibitor of the rHuR-RNA interaction. (A) AlphaScreen HTS carried out using 
1 nM of rHuR, 50 nM of BiTNF RNA probe and 50 nM of 107 anti-inflammatory compounds (see Table S1). 
(B) Representative REMSA performed with 0.5 μ M of rHuR and 0.5 μ M of Cy-3 RNA probe at equilibrium, 
showing the inhibitory activity of DHTS and its un-efficacy to electrophoretic mobility of the free RNA 
even at 100 μ M. (C) Saturation binding by REMSA or (D) by AlphaScreen assays evaluating DHTS activity 
in low micromolar or nanomolar range, respectively. (E) Kinetic experiments showing association (k3) and 
dissociation (k4) rate constants of DHTS. (F) Kinetic experiments performed upon pre-incubation of 1 nM 
of rHuR with different concentrations of DHTS before addition of 50 nM of BiTNF probe. (G) Dissociation 
experiments performed upon 30 min pre-incubation of 1 nM of rHuR and 50 nM of RNA (Ligands), or 
30 min pre-incubation of Ligands+beads, before addition of DHTS. Mean ± SD refers to three independent 
experiments (n = 3).
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earlier time point (3 h), no caspase activation was observed with 1 μ M of DHTS (Fig. 3B) and total RNA 
was actively transcribed (Fig. 3C and Supplementary Fig. S2A). Therefore, we used 1 μ M DHTS treatment 
at 3 h as reference condition to further characterize the impact of DHTS on HuR activity, and to reason-
ably exclude the induction of dramatic molecular events associated with cytotoxicity of the compound. 
DHTS alone or in combination with 3 h LPS stimulation (100 ng/ml) reduced TNF levels in stimulated 
Figure 2. DHTS inhibits HuR’s first RRMs and is not effective against other RBPs, HuD excluded; 
in vitro activity of other tanshinones. (A) Representative gels of at least three independent protein 
preparations of recombinant M1_M2 and M2_M3 HuR proteins. REMSAs were performed with 0.5 μ M of 
protein, 0.5 μ M of Cy-3 RNA probe and DMSO or DHTS at indicated doses. (B) Quantification of specific 
HuR-RNA binding challenged by indicated concentrations of commercially available tanshinones, including 
cryptotanshinone; TanI and TanII that were not included in the first screening. (C) Evaluation of DHTS 
activity at the indicated concentrations against Lin28b, TTP, HuD, and TDP-43 RNA-binding proteins tested 
by REMSA with 0.5 μ M of Cy-3 RNA as indicated in methods. Mean ± SD refers to three independent 
experiments (n = 3).
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mouse RAW264.7 cell line (Supplementary Fig. S2B)26. Since chronic production of TNF influences the 
phenotype of breast cancer cells by inducing secondary cytokines production and by impacting their 
growth and metastatic potential27, we studied the effect of DHTS on the regulation of TNF in human 
breast cancer cell lines. Exposure of breast cancer cells to 1 μ M of DHTS for 3 h significantly reduced 
total TNF mRNA levels to ≈ 40% (P < 0.05) of the control levels (Fig. 3D and Supplementary Fig. S2C). 
Treatment with 1 μ g/ml of LPS to MCF-7 (TLR4 positive) enhanced the TNF mRNA levels (P < 0.01), 
while treatment with DHTS counteracted the LPS-induced up-regulation (P < 0.001) (Fig. 3D). MCF-7 
cells expressed almost undetectable levels of TNF protein, and the endogenous (pro-TNF) protein could 
not be detected by immunoblotting in standard conditions. However, massive stimulation of pro-TNF 
production via exposure of MCF-7 cells to E. coli cells, and subsequent administration of DHTS, 
showed the efficacy of the compound in attenuating the production of pro-TNF (Supplementary Fig. 
S2D). Similarly, endogenous secreted TNF (sTNF, Fig. 3E) was hardly detectable under basal conditions, 
but protein level increased after LPS treatment and decreased markedly after 3 h treatment by DHTS 
(P < 0.01). These data show that DHTS first reduces the TNF mRNA expression level, and subsequently 
Figure 3. DHTS toxicity and inhibition of TNF in MCF-7 cells. (A) CellTiter-Glo assays upon exposure  
of MCF-7 cells to DHTS for 24 h. Relative IC50 was calculated by nonlinear regression curve fitting.  
(B) Apoptosis evaluation by 3/7 Caspase-Glo luminescent assays (Promega) and normalization to trypan 
blu negative cells (n = 3). (C) High content imaging quantification of fluorescence intensity/cell population 
of EU-conjugated Alexa-488 after 3 h treatment of MCF-7 cells with 1 μ M of DHTS or 2 μ M of actinomycin 
D. (D) Q-RT-PCR of TNF mRNA levels. Relative abundance was normalized with GAPDH mRNA in 
MCF-7 cells. (E) ELISA measuring secreted TNF protein levels. We detected in Mock condition an average 
of 15 pg/ml of sTNF as obtained by titration with standards. Where not indicated, mean ± SD refers to four 
independent experiments (n = 4).
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the translation and secretion of the encoded protein, confirming the anti-inflammatory properties of the 
compound in these cellular models.
DHTS inhibits post-transcriptional effects of HuR in MCF-7 cells. To test whether DHTS influ-
ences the post-transcriptional control of TNF mRNA mediated by HuR we performed ribonucleoproteic 
immunoprecipitation (RIP) analyses. DHTS reduced the number of copies of TNF mRNA selectively 
bound by HuR in MCF-7 cells (Fig. 4A). The strong enrichment observed in LPS-stimulated cell extracts 
confirmed the functional role of HuR in the post-transcriptional control of TNF in human cancer cells 
(P < 0.001). Notably, this effect is not specific for TNF mRNA, since RIP analysis on other HuR reg-
ulated transcript demonstrated that the copy number of ERBB2, VEGF, and CCND1 mRNAs bound 
by HuR in the presence of DHTS is, with different extent, significantly less with respect to the con-
trol (Supplementary Fig. S3A). RNA pull-down experiments in lysates from DHTS-treated MCF-7 cells 
confirmed the inhibition of the association step leading to the HuR:RNA complex formation (Fig. 4B), 
being the differences of precipitated HuR protein in DHTS treated cells statistically significant (P < 0.05) 
comparing DHTS vs Mock using the biotinylated probe. The same trend was observed for DHTS+LPS vs 
LPS condition, although with a non-significant effect in these experiments. Another ARE-binding RBP, 
hnRNP-D/AUF1, also displayed differential RNA-binding activity, however we observed these differences 
exclusively upon stimulation with LPS. To understand whether DHTS influences the stability of TNF 
mRNA in a HuR-dependent manner, we used both a stable HuR-silenced MCF-7 clone (siHuR) and 
transiently HuR over-expressing MCF-7 (HuROE) cells in actinomycin D chase experiments (Fig. 4C). 
The expression level of HuR positively correlated with the relative abundance of total TNF mRNA in 
MCF-7 cells, upon simultaneous transcriptional block. Interestingly, DHTS significantly reduced TNF 
mRNA stability compared with mock cells (P < 0.01 at 60 min time point), and caused a slightly addi-
tive effect in siHuR cells. On the contrary, DHTS displayed less efficacy in HuROE cells, suggesting 
that HuR expression is able to counteract the destabilizing effect of DHTS on mature TNF mRNA. To 
better understand these functional relationships, we evaluated the stability of nuclear immature (pre-) 
TNF transcripts, confirming, although with different kinetics, the HuR-dependency of mRNA stability 
and the same effects induced by DHTS on mature RNA transcripts; Similar effects were not observed 
for GAPDH mRNA under the same experimental conditions (Fig.  4C). Given the emerging evidences 
regarding HuR functionality in pre-mRNA processing events28, candidate HuR pre-mRNA targets were 
chosen according to Mukherjee et al.28, and CD14 was chosen as a negative control lacking AREs14. The 
mRNA stability of individual mRNAs, in actinomycin D chase experiment at single time point, was 
differently regulated by HuR expression and, except for pre-CTCF mRNA, HuR silencing caused a reduc-
tion of pre-BRCA1, pre-MDM2, pre-MYBL2 and pre-NFATC3 mRNA stability (Supplementary Fig. S3B, 
compare bar 1 and 3), in agreement with reported data28. To a different extent, DHTS diminished the 
stability of all the pre-mRNAs except the non-target, ARE-lacking, CD14 pre-mRNA (Supplementary 
Fig. S3B, compare bars 1 to 2). The compound exhibited further destabilization of pre-mRNAs in HuR 
depleted cells (siHuR), with the exception of pre-NFATC3 mRNA (Supplementary Fig. S3B, compare 
bars 3 to 4 and 5 to 6). Strikingly, over-expression of HuR in HuROE cells rescued the destabiliza-
tion effect of DHTS to control levels (Supplementary Fig. S3B, compare bars 7 and 8), supporting the 
idea that HuR RNA-binding activity is a target of DHTS, and that this compound early impacts this 
post-transcriptional modulation.
DHTS reduces polysomal recruitment of cytoplasmic TNF mRNA. To evaluate if DHTS modi-
fies the recruitment of TNF mRNA to the translational machinery, we performed nuclear and cytoplas-
mic RNA purifications from MCF-7 cells treated with DHTS and/or LPS, respectively, and evaluated 
TNF mRNA levels by real-time PCR (Fig. 5A). Nuclear levels of the transcript were significantly reduced 
by DHTS both in case-control and in LPS-treated cells (of ~55% and ~31%, P < 0.001 and P < 0.05, 
respectively). The relative amount of cytoplasmic TNF mRNA was unchanged in DHTS-treated versus 
control cells, but was significantly reduced by DHTS treatment (~44%, P < 0.01) in LPS-stimulated cells. 
Therefore, DHTS down-regulated nuclear TNF mRNA and reduced cytoplasmic TNF mRNA only after 
LPS stimulation.
To functionally investigate the translational efficiency of TNF mRNA, we performed sucrose-gradient 
fractionations of cytoplasmic sub-polysomal (representative of non-translating monosomes) and poly-
somal RNAs (representative of actively translating poly-ribosomes). DHTS treatment was performed 
on MCF-7 cells as such (Fig. 5B), and on LPS-treated MCF-7 and RAW264.7 cells (Supplementary Fig. 
S4A, S4B, S4C). Overall polysomal profiles showed no qualitative differences between the conditions 
analyzed, but the distribution analysis of single mRNAs, i.e. GAPDH and TNF (Fig. 5C) demonstrated 
that treatment with DHTS clearly reduced the polysomal loading of TNF mRNA paralleled by an 
increased amount in the sub-polysomal fractions. These data are also supported by the quantification of 
the TNF mRNA in collected sub-polysomal (fraction 1 to 6) and polysomal (fraction 7 to 12) compart-
ments (Supplementary Fig. S4B). Notably, the effect of DHTS on poly/sub ratios increased significantly 
with concomitant LPS stimulation (P < 0.001). Accordingly, polysomal loading of mouse TNF mRNA 
was also affected by DHTS in stimulated RAW264.7 cells (Supplementary Fig. S4C), supporting the 
hypothesis that DHTS interferes with the cytoplasmic TNF mRNA fraction loaded on polysomes for its 
translation. Extensive literature data show that HuR enhances the stability and translation of its bound 
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Figure 4. DHTS inhibits intracellular HuR-mRNA association, influencing mRNA stability. (A) RNA 
immunoprecipitation using MCF-7 lysates obtained after 3 h of treatment with DMSO, 1 μ M of DHTS, 
1 μ g/ml of LPS, or DHTS+LPS co-treatment. (B) RNA pull down assays on MCF-7 lysates obtained as in 
(A) after 2 h incubation with BiTNF (ARE+) or BiTNFneg (ARE-) exogenous RNA probes. Graph shows 
densitometric analyses by Image J software (NIH). (C) mRNA stability evaluation of TNF, pre-TNF, and 
GAPDH after co-treatment with actinomycin (D) and DHTS of scramble, vector, HuR silenced (siHuR) and 
HuR over-expressing (HuROE) MCF-7 cells. Relative HuR expression levels are shown in the representative 
WB. Residual mRNA, plotted in log scale, was normalized to relative RNA18S5 mRNA levels. Mean ± SD 
refers to three independent experiments (n = 3).
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mRNA by favoring the polysomal recruitment of the transcript21. Western blot analyses on protein sam-
ples precipitated from polysomal fractions revealed that DHTS displaces HuR from heavy polysomal 
fractions in un-stimulated and LPS-stimulated cells (Fig. 5D). Notably, we could not detect alterations 
in the activation of the p38 MAPK pathway in RAW264.7 cells (Supplementary Fig. S4D), which is 
responsible for cytoplasmic re-localization of HuR and stabilization of TNF mRNA upon LPS stimula-
tion6. Similarly, treatment of 3 h with 1 μ M of DHTS did not affect sub-cellular localization of HuR in 
MCF-7 cells (Fig. 6A) and did not change HuR protein expression level (Fig. 6B). Nucleo-cytoplasmic 
fractionation confirmed DHTS-induced HuR nuclear localization (Fig. 6C) further supporting the loss 
of function of HuR in the cytoplasm and its reduced polysomal loading. Our data suggests that, at early 
time points, pharmacological inhibition of RNA loading on HuR by DHTS confines HuR into the nuclear 
compartment.
HuR expression influences the sensitivity of breast cancer cells to DHTS. Dose-response assays 
on HuR-silenced or -over-expressing MCF-7 cells revealed a different sensitivity to DHTS (IC50 at 24 h of 
0.45 or 1.3 μ M compared with scramble or vector MCF-7 cells, respectively) (Fig. 7A), showing a com-
pensatory effect of HuR against DHTS. Interestingly, ectopic expression of TNF CDS alone, with 3′ UTR 
and ARE or with 3′ UTR but without ARE, did not influence the sensitivity of cells to 1 μ M of DHTS 
(Fig. 7B). This indicates that TNF itself is not responsible for this phenotypic response and that it can 
depend on the dysregulation of other factors regulated by HuR or, also, on independent events trigger-
ing the apoptotic pathways (Figs 3B, 7A). Real-time cell analysis assays demonstrated that DHTS exerts 
anti-proliferative effects at low doses (1 μ M), in MCF-7 cells after about 12 h of treatment (Fig. 7C). At 
Figure 5. DHTS decreases TNF mRNA translational efficiency in MCF-7 cells. (A) Q-RT-PCR showing 
relative nuclear or cytoplasmic amounts of TNF mRNA after 3 h treatment, normalized with GAPDH 
mRNA levels. (B) Polysomal profiles of cytoplasmic RNA of MCF-7 treated for 3 h with DMSO or 1 μ M of 
DHTS. (C) Q-RT-PCR analysis of GAPDH and TNF mRNA levels in single cytoplasmic RNA fractions.  
(D) Representative WB showing the distribution of HuR and RPL26 ribosomal protein in single fractions 
(left); densitometric analysis of relative cytoplasmic HuR protein levels in polysomal fractions. Mean ± SD 
refers to three independent experiments (n = 3).
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higher doses (10 μ M) cytotoxic effects of the compound appeared in this experimental system, and were 
confirmed by MTT (data not shown). HuR-silenced MCF-7 cells showed a decreased proliferative rate, 
and DHTS treatment completely blocked cell proliferation. Conversely, the proliferative potential of HuR 
over-expressing cells was considerably influenced by 1 μ M of DHTS compared with control (Fig.  7D), 
indicating that HuR dosage can modulate phenotypic response of these cells to low DHTS doses.
To better understand the phenotypic effect related with down-regulation of HuR-dependent and/or 
signaling molecules such as TNF, we then investigated the chemotactic potential of DHTS-treated, MCF-7 
conditioned medium using MDA-MB-231 trans-well migration as read-out, because the migration ability 
of MDA-MB-231 cells also depends on the presence of TNF and other cytokines in the surrounding 
environment29. DHTS treated medium strongly inhibited MDA-MB-231 migration more effectively than 
HuR depletion, whereas the DHTS treatment in siHuR cells produced an almost chemotactic inactive 
medium (Fig. 7E, left panel). Once again, HuR over-expression completely rescued DHTS efficacy and 
the corresponding medium was equally effective as the control medium. Notably, HuR over-expression 
per se did not produce an increased chemotactic medium (Fig. 7E, right panel). Taken all together, these 
data show that HuR completely rescues at least three phenotypic effects of DHTS, such as direct viability 
and proliferation inhibition on cancer cells and autocrine/paracrine inhibition of cancer cell migration. 
This suggests that HuR is a pivotal intracellular target of DHTS and that multi-target effects of DHTS, 
and eventually of tanshinones, can be explained by the inhibition of RNA-binding activity of HuR.
Discussion
In this study we show that DHTS is a potent inhibitor of the HuR:RNA interaction, active in the low 
nanomolar range, mainly by limiting the association rate of HuR with RNA. This inhibition is function-
ally recapitulated in our cellular models, in which the known, DHTS induced down-regulation of TNF 
expression can be largely ascribed to the loss of function of HuR, that no longer stabilizes TNF mRNA 
neither mediates its polysomal loading. This molecular mechanism of action has a therapeutic relevance, 
as shown by the inhibitory effect on viability, proliferation and chemotaxis of breast cancer cell lines and 
Figure 6. Effect of DHTS on HuR sub-cellular localization. (A) Representative immunofluorescence 
showing nuclei (Hoechst) or endogenous HuR (green) in MCF-7 cells treated with 1 μ M DHTS or 2 μ M 
of Actinomycin for 3 hD. (B) Representative western blot of total protein levels of HuR. (C) Western blot 
analysis on nuclear and cytoplasmic extracts of MCF-7 treated as in A. Densitometric analysis plot data of 
three independent experiments (n = 3).
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by the decreased TNF production in macrophages cells. Remarkably, the molecular and phenotypic 
effects induced by short-term and low doses of DHTS in breast cancer cell lines are rescued by the 
over-expression of HuR, confirming the cellular interaction between these two molecules. HuR 
over-expression in cancer tissues and the mechanistic role in mediating the inflammatory process has 
suggested that its inhibition could be beneficial in these pathologies22,30,31. In addition, HuR has been 
proposed as a drug target in cardiovascular diseases, nephropathy and diabetic retinopathy32–34. Several 
in vitro studies14,23,35 introduced some naturally occurring small molecule as HuR inhibitors, however the 
correlation among their post-transcriptional mechanism, biological effect and specificity, and therapeutic 
Figure 7. Efficacy of DHTS is dependent on HuR in breast cancer cell lines. (A) MTT assays on MCF-7 
cells genetically ablated or over-expressing HuR and treated for 24 h with DMSO or DHTS. (B) MTT assays 
on MCF-7 un-transfected or transfected with pUNO1-hTNFA (TNF), pUNO1-hTNFA/3′ UTR (TNF+3′), 
or pUNO1-hTNFA/3′ UTR-ARE (TNFΔ ARE) plasmids, then treated as in A. Western blot shows relative 
amount resulting from ectopic expression of TNF. (C,D) RTCA proliferation assays. Arrows indicate 
the treatment point with DMSO or the indicated doses of DHTS (symbol of vector DMSO condition is 
behind HuROE DHTS in the figure). (E) RTCA migration assays. Complete media of SCR, vector, siHuR, 
and HuROE MCF-7 cells treated for 3 h with DMSO, 1 μ M of DHTS 1 μ g/ml of LPS (vector cells only 
for positive control) were diluted to obtain 1% FBS final concentration. MDA-MB-231 cells were equally 
seeded (20,000/well) in each well of the upper chamber. SCR; stably transfected cells with non targeting 
shRNA, siHuR; stably transfected cells with HuR targeting shRNA, vector; transient transfected cells with 
empty vector, HuROE; transient transfected cells with HuR expressing vector. Mean ± SD refers to three 
independent experiments (n = 3).
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usefulness remains elusive. The most noteworthy example is the naphthofuranone MS-444, that was 
identified by a screening campaign on ≈ 50,000 natural product extracts using confocal fluctuation spec-
troscopic assays14. MS-444 has been shown to inhibit the HuR:RNA interaction by blocking the dimeri-
zation of HuR upon binding to the target RNA with a Kd around 40 nM. We did not investigate if DHTS 
acts via a similar inhibition of HuR dimerization. MS-444 has been recently used as a mechanistic tool 
to prevent HuR binding to miR-1636 and to TDP-43 and FUS mRNA37, although at higher concentrations 
than DHTS. In a recent effort compounds with a coumarin-derived core, which interfere with the func-
tion of HuR in the nanomolar range, have been identified using fluorescence polarization. This class of 
compounds shows anticancer properties in cell lines by inhibition of the expression of anti-apoptotic 
HuR targets, such as Bcl-2, Msi1 and XIAP38. In our case, having RNA-binding activity as functional 
read-out, we measured a strong, nanomolar inhibition of the association rate constant between HuR and 
RNA in vitro that was also specific to HuR and not to other RBPs as Lin28b, TDP-43 and TTP. In par-
ticular, we observed a ≈ 60% reduction in the number of TNF mRNA copies, as well as, with different 
extent, for ERBB2, VEGF, and CCND1 transcripts, using 1 μ M of DHTS by RIP experiments. Consistently, 
pull down experiments confirmed this effect although the magnitude of the interference was smaller 
(~40%), being limited by the use of a competitive exogenous RNA probe. The inhibitory effect of DHTS 
on AUF1 protein upon stimulation with LPS (Fig. 4B) could be ascribed to different mechanisms such 
as a diminished affinity for RNA or to an increased affinity for DHTS due to post-translational modifi-
cations, therefore we can not exclude a multi-targeting effect of DHTS in this condition. We did not 
observe a DHTS-induced activation of the p38 MAPK pathway nor HuR localization to the cytoplasm, 
further supporting the DHTS-induced HuR inhibition within cells and the utilization of DHTS in those 
cancer where HuR cytoplasmic localization plays a relevant role31. DHTS belongs to a family of natural 
diterpenes called tanshinones. Their anti-inflammatory, anti-atherosclerosis, cardioprotective and 
anti-cancer properties have been exploited in traditional Chinese medicine and are now under clinical 
investigation, but their exact mechanism of action is still unclear17,39. In this context we disclose a previ-
ously unrecognized molecular mechanism of action, involving post-transcriptional regulation, that might 
contribute to explain the wide spectrum of activities of DHTS correlated with their well-known inhibi-
tion of TNF. In particular, tanshinone I inhibits growth, invasion and angiogenesis on human breast 
cancer cells MDA-MB-231, both in vitro and in vivo, by decreasing the TNF-induced VEGF production. 
Moreover it reduces the MDA-MB-231 adhesion properties by decreasing the TNF dependent pivotal 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (V-CAM) of endothelial 
cells29. The efficacy of tanshinones has also been related with reduced expression of interleukins such as 
IL-618, MMPs40, VEGF41 and COX-242. There are also indications that the modulatory properties on an 
inflammatory state upon administration of tanshinones occurs via post-transcriptional repression of spe-
cific miRNAs, as in the case of miRNA-155 in colon cancer cells43. Interestingly, many of these key 
mRNAs and miRNAs are post-transcriptionally regulated by HuR8,20,44–47. Tanshinones have been shown 
to target or modulate several transcription factors, ion channels or hormone receptors within the cell39. 
We show that an intriguing explanation to the multi-target spectrum of tanshinones, could rely on the 
inhibition of the post-transcriptional function of HuR. Importantly resveratrol that has been shown to 
post-transcriptionally modulate TNF through KSRP regulation, providing a valuable example of the 
importance of post-transcriptional modulation of mRNA processing in the control of inflammation16. 
We provide mechanistic data indicating that HuR-mediated post-transcriptional inhibition is a major 
component of the cellular response to DHTS and that its relevance is shown by the HuR dosage modu-
lation of cytotoxicity and migratory potential in breast cancer cells in response to DHTS. These findings 
suggest several important avenues for further research: (i) HuR-dependent regulation of TNF expression 
levels. Modulation of cytokines is a validated therapeutic strategy for the treatment of inflammatory 
disorders, and due to its predicted post-transcriptional regulation, it might be expected that administra-
tion of DHTS could attenuate the TNF protein levels rather than deplete TNF at systemic levels, such as 
a consequence of antibody-based therapeutic strategies48; (ii) DHTS as a tool to investigate the connections 
between cancer and inflammation based on modulation of post-transcriptional events. Once validated in 
vivo, the use of DHTS (or of some of its analogues with a better drug-like profile) for therapeutic pur-
poses could be conceived. A functional screening of anti-inflammatory agents allowed the identification 
of 15,16-dihydrotanshinone-I (DHTS) for its ability to inhibit a specific protein-RNA interaction. First, 
we have characterized the biochemical parameters of DHTS in virtue of its interference on the dynamic 
of HuR-RNA binding and anticipated a new molecular scaffold exerting a previous unrecognized bioac-
tivity. Second, we have reported mechanistic evidences, in human tumor and mouse macrophages cell 
lines, suggesting HuR among the early intracellular targets of DHTS. The loss of function of HuR in 
response to this agent explains the modulation of the stability and translational efficiency of target 
mRNAs. Third, we have shown that phenotypic response, in terms of migration and sensitivity, of breast 
cancer cells to DHTS is remarkably influenced by HuR expression. Overall, these findings advance the 
understanding of contribution of post-transcriptional control in mediating anti-inflammatory and 
anti-cancer effects of a class of natural compounds and expand the concept of “genome druggability” by 
adding the post-transcriptional activity of the RNA binding protein HuR as feasible event that can occur 
during a pharmacological treatment. Finally, we suggest a novel rationale for the use of tanshinones in 
human diseases where HuR is deregulated or has prognostic significance, as breast, colon or ovarian 
cancers.
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Methods
Cell culture. Human breast adenocarcinoma MCF-7 (ICLC; HTL95021), SKBR3 (ICLC; HTL03005), 
and MDA-MB-231 (ICLC; HTL99004) cell lines were cultured in standard DMEM medium and growth 
conditions. Stable HuR-silenced (siHuR) and scramble (SCR) MCF-7 cells were obtained by infection 
with HuR shRNA- (ELAVL1 MISSION, Sigma, TRCN0000285492) and control shRNA (plasmid 1864, 
Addgene)-containing lentiviral particles, respectively; clones were selected with 5 μ g/ml puromycin. 
MCF-7 over-expressing (HuROE) cells were obtained by transient transfection with Lipofectamine 2000 
(Life Technologies; 11668-019) of pCMV6-HuR vector23. For endogenous TNF, MCF-7 cells (5*10^4/
well) were seeded in 6-well plates and grown under standard conditions for 24 h. Approximately 10^3 
DH5α E. coli cells were then inoculated for overnight co-culture in DMEM without antibiotics. After PBS 
washing steps, MCF-7 cells were treated for 3 h in complete medium with DHTS or DMSO. RAW264.7 
monocytes were grown as MCF-7 but in DMEM plus 0.1 mM non-essential amino acids mixture (Life 
Technologies, 11140).
Compounds and primary antibodies. Anti-inflammatory drugs used in the screening were 
cherry picked from the Spectrum Collection (MicroSource Discovery). Dihydrotanshinone I (D0947), 
Tanshinone I (T5330), Tanshinone IIA (T4952), Cryptotanshinone (C5624), and actinomycin D (A9400) 
were purchased from Sigma and dissolved in ultrapure dimethylsulfoxide (DMSO, Amresco, N182) to 
10 mM final concentration. List of antibodies: anti-HuR (sc-71290), anti-TNF (sc-1351), anti-Actin (sc-
1616) from Santa Cruz Biotechnology; mouse anti-GAPDH (MAB374) from EMD/Millipore; anti-RPL26 
(ab59567) and anti-6x His (ab1187) from Abcam; TTP antiserum (SAK21B) was a kind gift from Dr. 
A.R. Clark49 (Centre for Translational Inflammation Research, University of Birmingham, Birmingham, 
UK).
Expression and purification of HuR isoforms. The full-lenght sequence of HuR (NP_001410.20) 
in pCMV-HuR recombinant vector50 was used as template for PCR using M1_M2 
(5′ -CCCGCATATGATGTCTAATGGTTATG and 5′ -TATACTCGAGGCGAGAGGAGTGCC) and M2_
M3 (5′ - CCGCATATGATGACCCAGAAGGACGTA and 5′ - GGCCTCGAGTTTGTGGGACTTGT) 
primers. Inserts were sub-cloned in NdeI/XhoI-digested pET-42a vector (kindly provided by dr. Filipowicz’s 
lab, FMI, Basel, Switzerland) to produce M1_M2 (aa 1 to 197; predicted molecular weight: 22 kDa) and M2_
M3 (aa 117 to 326; predicted molecular weight: 24 kDa) His-tagged proteins, respectively. Sub-cloning of 
single domains was obtained with the following primers: M1 (5′ -CCCGCATATGATGTCTAATGGTTATG 
and 5′ -CCGCTCGAGTACGTCCTTCTGGG); M2 (5′ -CCGCATATGATGACCCAGAAGGACGTA and 
5′ -GGCTCGAGTCGCGCTGGCGAGT); M3 (5′ -GGCATATGTCCTCCGGCTGGTGCAT and 5′ -GGCC 
TCGAGTTTGTGGGACTTGT). Protein expression and purifications were performed as already 
described51. Purity of eluates was evaluated by 15% SDS-PAGE and Coomassie staining; single bands 
were quantified using ImageJ 1.4 software (NIH) with respect to known amount of loaded BSA.
AlphaScreen and electrophoresis mobility shift (REMSA) assays. Recombinant HuR-cMyc- 
His protein preparation, REMSAs with a fluorescent RNA probe (5′ -Cy3-AUUAUUUAUUAUU 
UAUUUAUUAUUUA), AlphaScreen with a 5′ -biotinylated RNA probe (BiTNF, 5′ -AUUAUUUAUUAUU 
UAUUUAUUAUUUA), and screening assays were carried out as already described23. Equilibrium disso-
ciation constants (Ki) of DHTS were fitted according to 1-site competition model in GraphPad Prism® , 
version 5.0 (GraphPad Software, Inc., San Diego, CA), keeping constant the RNA concentration (50 nM) 
and the Kd of the reaction at equilibrium (2.5 nM). IC50 values were obtained by nonlinear regression 
of log(dose)-response fit using the same software. Time course experiments were performed by reacting 
ligands and DHTS simultaneously, or by pre-incubating DHTS with rHuR or RNA. Dissociation exper-
iments were performed upon 30 min pre-incubation of 1 nM of rHuR and 50 nM of RNA plus beads 
(“Ligands+beads” in Fig. 1G), before addition of DHTS. To exclude possible interference of beads on dis-
sociation kinetics protein and RNA (“Ligands” in Fig. 1G) were pre-incubated for 30 min, then DHTS, at 
the indicated concentrations, and, finally, beads were added. Curves were fitted according to the kinetics of 
competitive binding model in GraphPad software, keeping constant the kon (2.76 ± 0.56*10^6 M–1 min–1) 
and koff (0.007 ± 0.005 min–1) of the reaction. DHTS analogs were tested by REMSA at the indicated con-
centrations and at equilibrium52. Plasmids encoding recombinant Lin28b-cMyc-His, TDP-43-His, and 
HuD-His were kindly provided by Prof. Quattrone’s lab (CIBIO, University of Trento, Italy). TTP, Lin28b, 
and HuD were expressed in HEK293T cells and purified following the protocols reported in23, with 
exception of buffers for Lin28b purification that were supplemented with 15 μ M ZnCl2. REMSAs were 
performed using the fluorescent AU-rich RNA probe to test TTP and HuD protein activities, whereas 
Lin28b binding was tested against pre-let7g (5′ -Cy3-GUCUAUGAUACCACCCGGUACAGGAGAU)53 
and TDP-43 against the 5′ -Cy3-CCGGGGCCGGGGCCGGGGCCGGGG RNA probes. Further details 
about biochemical experiments in the supplemental information.
Nucleo-cytoplasmic cell fractionation and qPCR. For nucleo-cytoplasmic fractionation, cells 
(4–6*10^6/sample) were re-suspended in buffer C (20 mMTris-HCl pH 7.5, 75 mM NaCl, 5 mM MgCl2, 
0.5% p/w sodium deoxycholate, 0.2% Triton, 1 mM DTT, 0.5% glycerol) plus protease inhibitor cock-
tail (Sigma, P8340) and 1 U/μ l RNAse inhibitor (Thermo Scientific, EO0381). After centrifugation 
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supernatants were collected (cytoplasmic lysates), whereas pelleted nuclei were re-suspended in buffer N 
(10 mM Tris-HCl pH 8, 25 mM NaCl, 5 mM MgCl2, 1% p/w sodium deoxycholate, 1% Triton, 0.2% SDS, 
1 mM DTT) plus protease and RNAse inhibitors and sonicated as above. TRIzol reagent (Life Technologies, 
12183-555) was used for RNA isolation. Quantitative PCRs, after cDNA Synthesis (Thermo Scientific, 
K1612) with equimolar mix of random and oligo-dT primers and two micrograms of template RNA, 
were performed using Universal SYBR Master Mix (KAPA Biosystems, KR0389) on CFX-96/384 thermal 
cyclers (BIO-RAD). 2−ΔΔCt method was used for quantification of mRNAs. Forward and reverse prim-
ers used: RNA18S5 (GCAGCTAGGAATAATGGAATAG and TGGCAAATGCTTTCGCTCTG), TNF 
(5′ -GGGACCTCTCTCTAATCAGC and 5′ -TCAGCTTGAGGGTTTGCTAC), GAPDH (5′ -CAAGGTCA 
TCCATGACAACTT and 5′ -GTCCACCACCCTGTTGCTGTA), CD14 (5′ -GAAGCT AAAGCACTTCCA 
GAGC and 5′ -TTCATCGTCCAGCTCACAAG), ERBB2 (GGTACTGAAAGCCTTAGGGAAGC and AC 
ACCATTGCTGTTCCTTCCTC), VEGF (CCGCAGACGTGTAAATGTTCCT and CGGCTTGTCACAT 
CTGCAAGTA), and CCND1 (CAGAACACGGCTCACGCTTAC and CTTGCCCCATCACGACAGAC). 
Primers for pre-TNF, pre-BRCA1, pre-CTCF, pre-MDM2, pre-MYBL2, and pre-NFATC3 are described 
elsewhere28.
Polysomal profiling and protein/RNA isolation. For polysomal RNA profiling, cytoplasmic lysates 
of 2*10^7 MCF-7 cells/sample were subjected to 15–50% sucrose gradient ultracentrifugation and frac-
tionation following reported protocols6,54,55. Aliquots of cytoplasmic lysates were considered for normal-
ization. From each sub-polysomal or polysomal fraction, protein samples were obtained by precipitation 
with 10% final concentration of trichloroacetic acid (TCA), while RNAs were isolated by TRIzol reagent 
(1:5 v/v). Fractions 1 to 6 were pooled to represent sub-polysomal RNA samples, while pooling of frac-
tions 7 to 12 represented polysomal RNA samples.
RNA immunoprecipitation (RIP) and RNA pull-down assays. Five*10^6 cells/sample were used 
for each RIP experiment, performed as described in56 without cross-linking steps and using 0.8 μ g/
ml of anti-Hu antibody or of mouse IgG isotype (negative control). TRIzol reagent was added directly 
to the beads for HuR-bound RNA isolation. Fold enrichment was calculated as 2e-Δ Ct, Δ Ct = target 
mRNA IP HuR/(target mRNA IgG). For RNA pull-down assays, MCF-7 cells were lysed in buffer R 
(20 mM HEPES pH 7.5, 50 mM KCl, 0.5 μ g BSA, 0.25% Glycerol, + protease and RNAse inhibitors) by 
sonication (80 amplitude with 6–7 cycles of 7” on and 45” off) at 4 °C. Clear lysates (0.2 μ m-filtered) 
were incubated for 1 h at 4 °C with 0.5 μ M of positive (BiTNF) or negative biotinylated (BiTNFneg, 
5′ -ACCACCCACCACCCACCCACCACCCA) RNA probes23. Solutions were incubated for further 2 h 
with 30 μ l/samples of streptavidin magnetic beads (Life technologies, 11205D). Specific protein enrich-
ments in beads-precipitated samples were analyzed by immunoblotting and densitometric analysis 
obtained using Image J 1.4 software (NIH).
RNA stability assays. SCR, siHuR, vector, and HuROE MCF-7 cells were co-treated with Act-D 
(2 μ M) and DMSO or DHTS for 3 h. Kinetics for mRNA stability evaluation has been carried out by 
extracting RNA in five time points (0, 30, 60, 120, 240 min) to be used for cDNA synthesis and quanti-
tative PCR analyses. Residual levels of target mRNAs were normalized to those of RNA18S5, and data 
were plotted as function of time with respect 0 min condition.
Cytotoxicity, Click-iT and RTCA assays. Sensitivity to DHTS was evaluated by CellTiter-Glo® 
(Promega, G7570), alamarBlue or MTT reagents following suggested protocols.
Ectopic expression of human TNF has been obtained with the pUNO1-hTNFA (Invivogen) plas-
mid. Inserts for recombinant pUNO-hTNFA/3′ UTR and pUNO-hTNFA/3′ UTRΔ ARE plasmids have 
been obtained by digestion of pBS vectors57,58, respectively, with XbaI and then blunt-end ligated in 
pUNO1-hTNFA vector digested with NheI restriction enzyme. Sequencing confirmed the results.
Apoptosis was evaluated by Caspase-Glo® 3/7 luminescent assay (Promega, G8090) upon normaliza-
tion to the number of trypan blue negative cells. RNA transcription was assessed using Click-iT® RNA 
Alexa Fluor® 488 Imaging Kit (Life Technologies, C10330). EthynylUridine (EU) was added 30 min 
before fixation, permeabilization and Click-iT reaction. Fluorescence signals relative to nascent RNA 
and nuclei (Hoechst 33342) were detected with Operetta instrument (PerkinElmer)and analyzed with 
Harmony 3.5.2 software (PerkinElmer). Proliferation assays were carried out with the xCELLigence 
RTCA DP Instrument (Roche) by plating 5,000 cells/well at t0 in E-Plate-16 format. Parallel plates were 
used to check the magnitude of HuR silencing or over-expression. Migration assays were performed 
using the same instrument and settings for CIM-Plates-16 (Roche), using media (1% FBS) of MCF-7 cells 
in the lower chamber and MDA-MB-231 cells equally seeded (20,000/well/160 μ l) in the upper chamber.
Immunoblotting and Enzyme-linked immunosorbent (ELISA) assay. Total, nuclear, and cyto-
plasmic cell extracts were subjected to 15%-SDS-PAGE and resolved proteins were transferred to nitro-
cellulose membrane (Millipore, IPVH00010) as previously described59. ELISA assays were carried out 
using Human TNF kit (Thermo Scientific, EH3TNFA) and the suggested protocol using surnatants of 
95%-confluent MCF-7 cells at time of treatment, seeded in 12-well plates.
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Statistical analysis. All data are expressed as means ± SD from three to four independent experi-
ments and statistics was performed using one-way ANOVA with Bonferroni’s multiple comparison test 
and Alpha level of 0.05. Magnitude of significance was also evaluated by student t-test and probability 
(P) values <0.05, <0.01, and <0.001 were indicated with *, **, *** symbols, respectively.
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